APOE — Apolipoprotein E
Chromosome 19q13.32
Lipid transport, cholesterol metabolism, neuronal repair, and amyloid-beta clearance in the brain. APOE is the major genetic risk modulator for late-onset Alzheimer's disease.
Pharmacogenomic Variants
Peptide Therapeutic Approaches
HDL-mimetic peptides (4F, D-4F), APOE-receptor interaction modulators (CS6253), and aggregation inhibitors targeting the lipid-binding domain.
Related Therapeutics
Associated Conditions
The most common neurodegenerative disease, characterized by progressive memory loss, cognitive decline, and amyloid-beta plaque accumulation. Genetic factors account for 60-80% of risk, with APOE4 being the strongest common risk allele.
Cardiovascular Disease (Genetic Risk)Genetic variants in APOE, AGT, AGTR1, and lipid metabolism genes contribute to cardiovascular risk. Pharmacogenomics guides anticoagulant, antiplatelet, and antihypertensive therapy selection.
Analyze APOE variants with PepFold
Submit rs429358, rs7412 and get ranked peptide candidates in under 2 minutes.